Insider Buying: Sensus Healthcare (NASDAQ:SRTS) Director Buys $112,765.25 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta bought 34,697 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was acquired at an average cost of $3.25 per share, with a total value of $112,765.25. Following the transaction, the director owned 209,310 shares of the company’s stock, valued at $680,257.50. This represents a 19.87% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Sensus Healthcare Price Performance

SRTS stock traded down $0.07 during midday trading on Tuesday, hitting $3.42. The company’s stock had a trading volume of 23,189 shares, compared to its average volume of 65,146. The company’s fifty day moving average price is $3.00 and its 200 day moving average price is $3.56. Sensus Healthcare, Inc. has a twelve month low of $2.66 and a twelve month high of $5.49. The stock has a market capitalization of $56.38 million, a P/E ratio of -3.64 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.

Institutional Trading of Sensus Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of SRTS. Pacific Ridge Capital Partners LLC boosted its stake in shares of Sensus Healthcare by 21.8% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after acquiring an additional 125,245 shares during the period. Geode Capital Management LLC raised its stake in Sensus Healthcare by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock valued at $630,000 after acquiring an additional 5,316 shares during the period. Sachetta LLC lifted its holdings in Sensus Healthcare by 6.8% during the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after purchasing an additional 9,500 shares during the last quarter. Greenline Wealth Management LLC bought a new position in Sensus Healthcare during the fourth quarter worth $513,000. Finally, North Star Investment Management Corp. bought a new position in Sensus Healthcare during the first quarter worth $500,000. Institutional investors own 25.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Lake Street Capital lowered their price target on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensus Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $5.83.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.